Home | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Contact | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Careers | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Products | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE ...
Mar 3, 2026 · Harrow believes the planned Phase 3 trial represents an important opportunity to further strengthen the clinical and commercial profile of TRIESENCE. The study is designed to generate …
0001493152-23-008718 | 10-K | Harrow, Inc.
Dec 31, 2022 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic ...
Jan 11, 2024 · Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry …
News | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
Harrow Announces Third Quarter 2025 Financial Results
NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the …
Stock Quote & Chart - Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.